Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rahul Aggarwal

Showing results (191-200 of 223) with videos related to

Pageof 23
Sort By:
Cancer Medicine|October 12, 2021
Feasibility, safety, and acceptability of a remotely monitored exercise pilot CHAMP: A Clinical trial of High-intensity Aerobic and resistance exercise for Metastatic castrate-resistant Prostate cancerStacey A Kenfield, Erin L Van Blarigan, Neil Panchal, et al.
Frontiers in Oncology|March 24, 2022
APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial CancerDivya Natesan, Li Zhang, Henry J Martell, et al.
Cancer Discovery|April 29, 2017
Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of <i>BRCA2</i> Reversion Mutations Associated with Resistance to PARP InhibitorsDavid Quigley, Joshi J Alumkal, Alexander W Wyatt, et al.
Nature|July 21, 2022
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancerCameron Herberts, Matti Annala, Joonatan Sipola, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2020
Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPETSinan Wang, Jun Li, Jun Hua, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 23, 2018
Phase I Study of CTT1057, an <sup>18</sup>F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate CancerSpencer C Behr, Rahul Aggarwal, Henry F VanBrocklin, et al.
Clinical Genitourinary Cancer|June 14, 2023
Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab VedotinTanya Jindal, Li Zhang, Prianka Deshmukh, et al.
Genome Biology|April 16, 2026
Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancerThaidy Moreno-Rodriguez, Meng Zhang, Arian Lundberg, et al.
The Lancet. Diabetes & Endocrinology|February 17, 2025
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trialRahul Aggarwal, Deepak L Bhatt, Michael Szarek, et al.
JCO Precision Oncology|November 15, 2021
Differential Activity of PARP Inhibitors in <i>BRCA1</i>- Versus <i>BRCA2</i>-Altered Metastatic Castration-Resistant Prostate CancerFadi Taza, Albert E Holler, Wei Fu, et al.
Pageof 23

Showing results (191-200 of 223) with videos related to

Sort By:
Pageof 23
Cancer Medicine|October 12, 2021
Feasibility, safety, and acceptability of a remotely monitored exercise pilot CHAMP: A Clinical trial of High-intensity Aerobic and resistance exercise for Metastatic castrate-resistant Prostate cancerStacey A Kenfield, Erin L Van Blarigan, Neil Panchal, et al.
Frontiers in Oncology|March 24, 2022
APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial CancerDivya Natesan, Li Zhang, Henry J Martell, et al.
Cancer Discovery|April 29, 2017
Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of <i>BRCA2</i> Reversion Mutations Associated with Resistance to PARP InhibitorsDavid Quigley, Joshi J Alumkal, Alexander W Wyatt, et al.
Nature|July 21, 2022
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancerCameron Herberts, Matti Annala, Joonatan Sipola, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2020
Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPETSinan Wang, Jun Li, Jun Hua, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 23, 2018
Phase I Study of CTT1057, an <sup>18</sup>F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate CancerSpencer C Behr, Rahul Aggarwal, Henry F VanBrocklin, et al.
Clinical Genitourinary Cancer|June 14, 2023
Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab VedotinTanya Jindal, Li Zhang, Prianka Deshmukh, et al.
Genome Biology|April 16, 2026
Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancerThaidy Moreno-Rodriguez, Meng Zhang, Arian Lundberg, et al.
The Lancet. Diabetes & Endocrinology|February 17, 2025
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trialRahul Aggarwal, Deepak L Bhatt, Michael Szarek, et al.
JCO Precision Oncology|November 15, 2021
Differential Activity of PARP Inhibitors in <i>BRCA1</i>- Versus <i>BRCA2</i>-Altered Metastatic Castration-Resistant Prostate CancerFadi Taza, Albert E Holler, Wei Fu, et al.
Pageof 23